MiR-99b was described to contribute to irradiation resistance in human pancreatic cancer by targeting mTOR [65], whose activity is also known to play a role in NAFLD-NASH [66–68]. Here, MTOR is linked to metabolic dysfunction-associated steatohepatitis.